title: [Antimalarial's retinopaty remains a current threat].
authors.forename: Anne
authors.initials: A
authors.lastname: Chiffoleau
authors.forename: Aurélie
authors.initials: A
authors.lastname: Guillet
authors.forename: Xavier
authors.initials: X
authors.lastname: Zanlonghi
authors.forename: Pascale
authors.initials: P
authors.lastname: Jolliet
mesh_terms: D000962:Antimalarials / Q000009:adverse effects* / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D002738:Chloroquine / Q000009:adverse effects* / Q000627:therapeutic use; D015331:Cohort Studies; D004305:Dose-Response Relationship, Drug; D005500:Follow-Up Studies; D006801:Humans; D006886:Hydroxychloroquine / Q000009:adverse effects* / Q000627:therapeutic use; D008134:Long-Term Care; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy; D008266:Macula Lutea / Q000187:drug effects*; D008288:Malaria / Q000517:prevention & control; D008875:Middle Aged; D012164:Retinal Diseases / Q000139:chemically induced* / Q000175:diagnosis; D012189:Retrospective Studies; D014786:Vision Disorders / Q000139:chemically induced / Q000175:diagnosis
chemical_list: D000962:Antimalarials; D006886:Hydroxychloroquine; D002738:Chloroquine